Clinical Trials Logo

Clinical Trial Summary

Antiphospholipid antibody syndrome (APS) is an autoimmune disease characterized by systemic thrombosis and bad obstetric history. APS secondary to another medical disorder is the most common. Visual and ocular changes e.g. vaso-occlusive disease of retinal and choroidal vessels are found in patients with secondary APS. Patients with primary APS have also been reported to have ocular changes e.g. retinal vascular occlusion

The aim of our study to detect prevalence of ocular changes in women diagnosed with primary APS and correlation of these changes with adverse obstetric outcome. If a correlation is present, ocular findings in women with APS could be used in the future as a predictor for poor obstetric outcome.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03459508
Study type Observational
Source Cairo University
Contact
Status Completed
Phase
Start date December 1, 2017
Completion date October 23, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01956188 - Omega 3 in LES and APS N/A
Recruiting NCT05904301 - Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Not yet recruiting NCT03540810 - Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome Phase 3